U.S. markets open in 6 hours 12 minutes
  • S&P Futures

    4,461.75
    +16.00 (+0.36%)
     
  • Dow Futures

    34,842.00
    +168.00 (+0.48%)
     
  • Nasdaq Futures

    15,358.50
    +39.75 (+0.26%)
     
  • Russell 2000 Futures

    2,256.00
    +12.00 (+0.53%)
     
  • Crude Oil

    74.78
    +0.80 (+1.08%)
     
  • Gold

    1,757.40
    +5.70 (+0.33%)
     
  • Silver

    22.65
    +0.23 (+1.00%)
     
  • EUR/USD

    1.1714
    -0.0004 (-0.04%)
     
  • 10-Yr Bond

    1.4600
    0.0000 (0.00%)
     
  • Vix

    17.75
    -0.88 (-4.72%)
     
  • GBP/USD

    1.3687
    +0.0007 (+0.05%)
     
  • USD/JPY

    110.6280
    -0.0570 (-0.05%)
     
  • BTC-USD

    43,770.97
    +1,750.25 (+4.17%)
     
  • CMC Crypto 200

    1,093.39
    -9.67 (-0.88%)
     
  • FTSE 100

    7,118.91
    +67.43 (+0.96%)
     
  • Nikkei 225

    30,240.06
    -8.75 (-0.03%)
     

Is Recursion Pharmaceuticals (RXRX) A Good Stock To Buy Now?

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Baron Discovery Fund recently published its second-quarter commentary – a copy of which can be downloaded here. During the second quarter of 2021, the Baron Discovery Fund returned 6.07% (institutional shares). In comparison, the benchmark S&P 500 Index was up 8.55%, while the Russell 2000 Growth Index was up 3.92%. You should check out Baron Discovery Fund’s top 5 stock picks for investors to buy right now, which could be the biggest winners of 2021.

In the Q2 2021 Investor Letter, the fund highlighted a few stocks and Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of them. Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is a biotechnology company. In the last three months, Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock lost 21%. Here is what the fund said:

"Recursion Pharmaceuticals, Inc. is a biotechnology company engaged in technology-enabled drug discovery. The company uses automated wet-lab infrastructure (actual biologic experimentation) with cell perturbations (multiple experiments done on the duplicate cells), and image capture to generate data at large scale. It also operates its own supercomputer (the “BioHive”) to drive “in-silico” (virtual, software-enabled) inferences based on its data and wet-lab experiments. This combined approach has generated a strong pipeline of programs spanning early discovery to clinical trials, including a collaboration deal with Bayer. The company’s use of artificial intelligence and machine learning lowers the cost of drug discovery and speeds up time to market, and we believe this paradigm is in the early innings of disrupting the entire biopharmaceutical industry. Since Recursion’s program pipeline is still relatively early stage, we have started with a small investment."

Pressmaster/Shutterstock.com

Our calculations showed that Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) isn't ranked among the 30 most popular stocks among hedge funds.

The top 10 stocks among hedge funds returned 231.2% between 2015 and 2020, and outperformed the S&P 500 Index ETFs by more than 126 percentage points. We know it sounds unbelievable. You have been dismissing our articles about top hedge fund stocks mostly because you were fed biased information by other media outlets about hedge funds' poor performance. You could have doubled the size of your nest egg by investing in the top hedge fund stocks instead of dumb S&P 500 ETFs. Here you can watch our video about the top 5 hedge fund stocks right now. All of these stocks had positive returns in 2020.

At Insider Monkey, we scour multiple sources to uncover the next great investment idea. For example, Federal Reserve has been creating trillions of dollars electronically to keep the interest rates near zero. We believe this will lead to inflation and boost real estate prices. So, we recommended this real estate stock to our monthly premium newsletter subscribers. We go through lists like the 10 best EV stocks to pick the next Tesla that will deliver a 10x return. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. You can subscribe to our free daily newsletter on our homepage.

Disclosure: None. This article is originally published at Insider Monkey.